SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Marco Taglietti purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average price of $1.61 per share, with a total value of $16,100.00. Following the completion of the acquisition, the chief executive officer now owns 287,000 shares of the company’s stock, valued at $462,070. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of SCYNEXIS, Inc. (NASDAQ SCYX) traded down 0.58% during trading on Thursday, reaching $1.70. The company’s stock had a trading volume of 34,341 shares. The firm’s market cap is $45.43 million. SCYNEXIS, Inc. has a 12 month low of $1.52 and a 12 month high of $5.51. The company’s 50 day moving average price is $1.76 and its 200 day moving average price is $2.31.

WARNING: “Insider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/17/insider-buying-scynexis-inc-scyx-ceo-buys-10000-shares-of-stock.html.

Several large investors have recently made changes to their positions in the stock. Iguana Healthcare Management LLC raised its stake in shares of SCYNEXIS by 20.0% in the first quarter. Iguana Healthcare Management LLC now owns 300,000 shares of the company’s stock valued at $828,000 after buying an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of SCYNEXIS by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock valued at $103,000 after buying an additional 512 shares during the last quarter. KCG Holdings Inc. acquired a new stake in shares of SCYNEXIS during the first quarter valued at approximately $416,000. Private Advisor Group LLC acquired a new stake in shares of SCYNEXIS during the first quarter valued at approximately $555,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of SCYNEXIS during the first quarter valued at approximately $154,000. Institutional investors own 48.53% of the company’s stock.

SCYX has been the subject of a number of recent research reports. Zacks Investment Research upgraded SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Wednesday, August 2nd. Aegis restated a “buy” rating on shares of SCYNEXIS in a research note on Tuesday, May 30th. Needham & Company LLC lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Tuesday, May 9th. Roth Capital set a $9.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, HC Wainwright set a $14.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $10.22.

About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.